The duality of oncomiR addiction in the maintenance and treatment of cancer

Cancer Journal (United States)

Volumn 18, Issue 3, 2012, Pages 232-237

  Cheng, Christopher J ^a   Slack, Frank J ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

anti miR; anticancer therapy; cell circuitry; microRNA; molecular targeting; oncogene; oncogenesis; OncomiR addiction; proto oncomiR; tumorigenesis

Indexed keywords

ANTAGOMIR; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETERNACEPT; K RAS PROTEIN; LOCKED NUCLEIC ACID; MICRORNA; MICRORNA 10B; MICRORNA 122; MICRORNA 125B; MICRORNA 132; MICRORNA 143; MICRORNA 145; MICRORNA 155; MICRORNA 21; MICRORNA 29; MYC PROTEIN; PEPTIDE NUCLEIC ACID; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; COLORECTAL CANCER; DOWN REGULATION; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GLIOBLASTOMA; HUMAN; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; NANOTECHNOLOGY; NEUROBLASTOMA; NONHUMAN; ONCOGENE; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SKIN CANCER; STOMACH CANCER; THYROID CANCER;

CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; NEOPLASMS; ONCOGENES;

EID: 84862182826     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318258b75b     Document Type: Review

References (76)

1. Djuranovic S, Nahvi A, Green R. A parsimonious model for gene regulation by miRNAs. Science. 2011;331:550-553.
2. Rajewsky N. MicroRNA target predictions in animals. Nat Genet. 2006; 38:S8YS13.
3. Ambros V. MicroRNAs: Tiny regulators with great potential. Cell. 2001; 107:823-826.
4. Volinia S, Calin GA, Liu C-G, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. PNAS. 2006;103: 2257-2261.
5. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and downregulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. PNAS. 2002;99:15524-15529.
6. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. PNAS. 2004;101:2999-3004.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100: 57-70.
8. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4:199-207.
9. Weinstein IB. Addiction to oncogenesVthe Achilles heal of cancer. Science. 2002;297:63-64.
10. Felsher DW. Oncogene addiction versus oncogene amnesia: Perhaps more than just a bad habit?Cancer Res. 2008;68:3081-3086.
11. Ma L, Reinhardt F, Pan E, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol. 2010; 28:341-347.
12. Fontana L, FioriME, Albini S, et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE. 2008;3-e2236.
13. Si M-L, Zhu S, Wu H, et al. MiR-21Ymediated tumor growth. Oncogene. 2006;26:2799-2803.
14. Yan LX,Wu QN, Zhang Y, et al. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res. 2011;13:R2.
15. Corsten MF, Miranda R, Kasmieh R, et al. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cellYdelivered S-TRAIL in human gliomas. Cancer Res. 2007;67:8994-9000.
16. Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-RasYdependent lung tumorigenesis by microRNA-21. Cancer Cell. 2010;18:282-293.
17. Frezzetti D, De Menna M, Zoppoli P, et al. Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene. 2011;30:275-286.
18. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21Yinduced preYB-cell lymphoma. Nature. 2010;467:86-90.
19. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452:896-899.
20. Anand S, Majeti BK, Acevedo LM, et al. MicroRNA-132Ymediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med. 2010;16:909-914.
21. Zhang X, Liu S, Hu T, et al. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology. 2009;50:490-499.
22. Pedersen IM, Otero D, Kao E, et al. Onco-miR-155 targets SHIP1 to promote TNFa-dependent growth of B cell lymphomas. EMBO Mol Med. 2009;1:288-295.
23. Babar IA, Cheng CJ, Booth CJ, et al. Nanoparticle-based therapy in an in vivo miR-155-dependent mouse model of lymphoma. PNAS. 2012. In press.
24. Swarbrick A, Woods SL, Shaw A, et al. MiR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCNamplified neuroblastoma. Nat Med. 2010;16:1134-1140.
25. Krichevsky AM, Gabriely G. MiR-21: A small multi-faceted RNA. J Cell Mol Med. 2009;13:39-53.
26. Liu L-Z, Li C, Chen Q, et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1> expression. PLoS One. 2011;6:e19139.
27. Asangani IA, Rasheed SAK, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27:2128-2136.
28. Sotiropoulou G, Pampalakis G, Lianidou E, et al. Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA. 2009;15:1443-1461.
29. Esquela-Kerscher A, Slack FJ. OncomirsVmicroRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259-269.
30. Pichiorri F, Suh S-S, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. PNAS. 2008;105: 12885-12890.
31. Costinean S, Zanesi N, Pekarsky Y, et al. PreYB cell proliferation and lymphoblastic leukemia/high-grade lymphoma in EK-miR155 transgenic mice. PNAS. 2006;103:7024-7029.
32. Eis PS, TamW, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. PNAS. 2005;102:3627-3632.
33. Tili E, Croce CM, Michaille J-J. MiR-155: On the crosstalk between inflammation and cancer. Int Rev Immunol. 2009;28:264-284.
34. Le MTN, Teh C, Shyh-Chang N, et al. MicroRNA-125b is a novel negative regulator of p53. Gene Dev. 2009;23:862-876.
35. Zhang Y, Yan L-X,Wu Q-N, et al. MiR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 2011;71:3552-3562.
36. Boldin MP, Taganov KD, Rao DS, et al. MiR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med. 2011;208:1189-1201.
37. Garcia AI, Buisson M, Bertrand P, et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med. 2011;3:279-290.
38. Pekarsky Y, Croce CM. Is miR-29 an oncogene or tumor suppressor in CLL?Oncotarget. 2010;1:224-227.
39. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11:849-864.
40. Tili E. Expression and function of micro RNAs in immune cells during normal or disease state. Int J Med Sci. 2008;5:73-79.
41. Folini M, Gandellini P, Longoni N, et al. MiR-21: An oncomir on strike in prostate cancer. Mol Cancer. 2010;9:12.
42. Mavrakis KJ, Leslie CS, Wendel H-G. Cooperative control of tumor suppressor genes by a network of oncogenic microRNAs. Cell Cycle. 2011; 10:2845-2849.
43. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167-179.
44. Jopling CL, Yi M, Lancaster AM, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science. 2005; 309:1577-1581.
45. Banaudha K, Kaliszewski M, Korolnek T, et al. MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. Hepatology. 2011;53:53-61.
46. Aguda BD, Kim Y, Piper-Hunter MG, et al. MicroRNA regulation of a cancer network: Consequences of the feedback loops involving miR-17- 92, E2F, and Myc. PNAS. 2008;105:19678-19683.
47. Johnston RJ, Chang S, Etchberger JF, et al.MicroRNAs acting in a doublenegative feedback loop to control a neuronal cell fate decision. PNAS. 2005;102:12449-12454.
48. Tokumaru S, Suzuki M, Yamada H, et al. Let-7 regulates Dicer expression and constitutes a negative feedback loop. Carcinogenesis. 2008;29: 2073-2077.
49. Pulikkan JA, Dengler V, Peramangalam PS, et al. Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood. 2010;115:1768-1778.
50. Yu Z,Wang C,Wang M, et al. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol. 2008;182:509-517.
51. O'Donnell KA, Wentzel EA, Zeller KI, et al. c-MycYregulated micro- RNAs modulate E2F1 expression. Nature. 2005;435:839-843.
52. Sylvestre Y, De Guire V, Querido E, et al. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 2007;282:2135-2143.
53. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Gene Dev. 1994;8:1514-1525.
54. Mendell JT. MiRiad roles for the miR-17-92 cluster in development and disease. Cell. 2008;133:217-222.
55. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435:828-833.
56. Jeang K-T. Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction?Oncotarget. 2010;1:453-456.
57. Linnstaedt SD, Gottwein E, Skalsky RL, et al. Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol. 2010;84:11670-11678.
58. Godshalk SE, Bhaduri-McIntosh S, Slack FJ. Epstein-Barr virusY mediated dysregulation of human microRNA expression. Cell Cycle. 2008;7:3595-3600.
59. Cai X, Lu S, Zhang Z, et al. Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. PNAS. 2005;102:5570-5575.
60. Gottwein E, Corcoran DL, Mukherjee N, et al. Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. Cell Host Microbe. 2011;10:515-526.
61. Chang S, Wang R-H, Akagi K, et al. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med. 2011;17: 1275-1282.
62. Watashi K, Yeung ML, Starost MF, et al. Identification of small molecules that suppress microRNA function and reverse tumorigenesis. J Biol Chem. 2010;285:24707-24716.
63. Lennox KA, Behlke MA. Chemical modification and design of antimiRNA oligonucleotides. Gene Ther. 2011;18:1111-1120.
64. Lu Y, Xiao J, Lin H, et al. A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res. 2009; 37:e24.
65. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with "antagomirs". Nature. 2005;438:685-689.
66. Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol. 2007;25: 1149-1157.
67. Stenvang J, Silahtaroglu AN, Lindow M, et al. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin Cancer Biol. 2008;18:89-102.
68. Stenvang J, Petri A, Lindow M, et al. Inhibition of microRNA function by antimiR oligonucleotides. Silence. 2012;3:1.
69. Sheridan C. Gene therapy finds its niche. Nat Biotechnol. 2011;29: 121-128.
70. Ebert MS, Sharp PA. MicroRNA sponges: Progress and possibilities. RNA. 2010;16:2043-2050.
71. Darido C, Georgy SR,Wilanowski T, et al. Targeting of the tumor suppressor GRHL3 by a miR-21Ydependent proto-oncogenic network results in PTEN loss and tumorigenesis. Cancer Cell. 2011;20: 635-648.
72. Haraguchi T, Ozaki Y, Iba H. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res. 2009;37:e43.
73. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4: 346-358.
74. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines. J Drug Target. 2007;15:457-464.
75. Su J, Baigude H, McCarroll J, et al. Silencing microRNA by interfering nanoparticles in mice. Nucleic Acids Res. 2011;39:e38.
76. Liu X-Q, SongW-J, Sun T-M, et al. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol Pharm. 2010;8:250-259.